

=> fil reg; d ide

~~FILE: 'REGISTRY'~~ ENTERED AT 15:06:34 ON 11 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7  
DICTIONARY FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 648864-11-3 REGISTRY  
ED Entered STN: 11 Feb 2004  
CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid  
FS 3D CONCORD  
MF C28 H19 Cl3 N2 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



*species*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil\_capl uspatf toxcenter; s 15  
 FILE 'CAPLUS' ENTERED AT 15:06:46 ON 11 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:06:46 ON 11 APR 2005  
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:06:46 ON 11 APR 2005  
 COPYRIGHT (C) 2005 ACS

L6 6 L5

=> dup\_rem\_16  
 PROCESSING COMPLETED FOR L6  
 L7 5 DUP REM L6 (1 DUPLICATE REMOVED)  
 ANSWERS '1-2' FROM FILE CAPLUS  
 ANSWERS '3-5' FROM FILE USPATFULL


=> d ibib ed abs hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2004:60479 CAPLUS  
 DOCUMENT NUMBER: 140:128414  
 TITLE: Preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1  
 receptor modulators  
 INVENTOR(S): Barrett, Terrance D.; Breitenbacher, J. Guy; Gomez,  
 Laurent; Hack, Michael D.; Huang, Liming; McClure,  
 Kelly J.; Morton, Magda F.; Sehorn, Clark A.;  
 Shankley, Nigel P.

*Barb's comment*

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.  
SOURCE: PCT Int. Appl., 326 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007463	A1	20040122	WO 2003-US20787	20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004067983	A1	20040408	US 2003-612150	20030702
PRIORITY APPLN. INFO.:			US 2002-393493P	P 20020703
OTHER SOURCE(S):		MARPAT 140:128414		
ED Entered STN:	26 Jan 2004			
GT				




AB The title compds. [I; R1 = 1- or 2-position substituent selected from H, (un)substituted Ph, naphthyl, etc.; R2 = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R3 = H, halo, alkyl; n = 0-2; R4 = H, halo, alkyl, absent; Ar = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R5 = CO<sub>2</sub>R<sub>6</sub> (wherein R<sub>6</sub> = H, alkyl), CONR<sub>7</sub>R<sub>8</sub> (R<sub>7</sub>, R<sub>8</sub> = H, alkyl, cycloalkyl; or NR<sub>7</sub>R<sub>8</sub> = 5-7 membered ring), tetrazolyl, etc.], useful as CCK-1 receptor modulators, were prepared. E.g., a multi-step synthesis of (S)-II which showed pKi of 8.0 against CCK-1 receptor binding, was given. Pharmaceutical composition comprising the title compound was claimed.

IT 648864-11-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 648864-11-3 CAPLUS (preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)







REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:55208 CAPLUS  
 DOCUMENT NUMBER: 142:155944  
 TITLE: Preparation of pyrazole derivatives as CCK-1 receptor modulators for the treatment of gastrointestinal and CNS disorders  
 INVENTOR(S): Choudhury, Anusuya; Grimm, Jeffrey S.; Jones, Todd K.; Liang, Jimmy T.; Mani, Neelakandha; Sorgi, Kirk L.  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.  
 SOURCE: PCT Int. Appl., 353 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005393	A2	20050120	WO 2004-US21020	20040630
WO 2005005393	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005020565	A1	20050127	US 2004-882077	20040630
US 2005026903	A1	20050203	US 2004-881628	20040630

PRIORITY APPLN. INFO.:

US 2003-484319P  
US 2003-484370PP 20030702  
P 20030702ED Entered STN: 20 Jan 2005  
GI

AB The invention relates to certain pyrazole based CCK-1 receptor modulators I [wherein R1 (1- or 2-position) = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl or alkyl; R2, Ar = (un)substituted Ph, naphthyl, cycloalkyl or heterocyclyl; R3 = H, halo or alkyl; n = 0-2; R4 = H, halo, alkyl or absent when the double bond is present; R5 = COOH, ester, amide or certain triazolylsulf(a/o/i)nyl; etc., or enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof] and methods for their preparation. For example, condensation of 3,4-dichloroacetophenone with di-Et oxalate in the presence of LiHMDS followed by regioselective cyclization with 4-methoxyphenylhydrazine hydrochloride gave pyrazole II (R = COOEt). This ester was then converted to iodide II (R = CH2I) via DIBAL reduction, mesylation with methanesulfonyl chloride and substitution with NaI. Enantioselective alkylation of chiral oxazolidinone III (preparation given) with II (R = CH2I) followed by hydrolysis mediated by H2O2-LiOH afforded IV. Sodium salt of IV showed affinity for CCK-1 receptor with pKi of 8.0. Therefore, I are useful in treating diseases mediated by CCK receptors, such as gastrointestinal and CNS disorders.


IT 648864-11-3P, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)

RN 648864-11-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:31466 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S): Choudhury, Anusuya, Churchville, PA, UNITED STATES  
 Grimm, Jeffrey S., Somerville, NJ, UNITED STATES  
 Liang, Jimmy T., San Diego, CA, UNITED STATES  
 Mani, Neelakandha, San Diego, CA, UNITED STATES  
 Sorgi, Kirk L., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026903	A1	20050203
APPLICATION INFO.:	US 2004-881628	A1	20040630 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-484370P	20030702 (60)
	US 2003-484319P	20030702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	

NUMBER OF CLAIMS: 172

EXEMPLARY CLAIM: 1

LINE COUNT: 8446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: ##STR1##


wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R.<sup>1</sup>, R.<sup>2</sup>, R.<sup>3</sup>, R.<sup>4</sup> and R.<sup>5</sup> are certain organic substituents, and methods of making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid  
(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)

RN 648864-11-3 USPATFULL

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:24016 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S): Jones, Todd K., Solana Beach, CA, UNITED STATES  
Liang, Jimmy T., San Diego, CA, UNITED STATES  
Mani, Neelakandha, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005020565 A1 20050127

APPLICATION INFO.: US 2004-882077 A1 20040630 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2003-484319P 20030702 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003

NUMBER OF CLAIMS: 289

EXEMPLARY CLAIM: 1

LINE COUNT: 9023

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: ##STR1##


wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R.<sup>1</sup>, R.<sup>2</sup>, R.<sup>3</sup>, R.<sup>4</sup> and R.<sup>5</sup> are certain organic substituents, and methods of making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid  
(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)

RN 648864-11-3 USPATFULL

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:89006 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S):  
 Barrett, Terrance D., Encinitas, CA, UNITED STATES  
 Breitenbucher, J. Guy, Escondido, CA, UNITED STATES  
 Gomez, Laurent, San Diego, CA, UNITED STATES  
 Hack, Michael D., San Diego, CA, UNITED STATES  
 Huang, Liming, San Diego, CA, UNITED STATES  
 McClure, Kelly J., San Diego, CA, UNITED STATES  
 Morton, Magda F., San Diego, CA, UNITED STATES  
 Sehon, Clark A., West Chester, PA, UNITED STATES  
 Shankley, Nigel P., Solana Beach, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004067983 A1 20040408

APPLICATION INFO.: US 2003-612150 A1 20030702 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-393493P 20020703 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003

NUMBER OF CLAIMS: 48

EXEMPLARY CLAIM: 1

LINE COUNT: 8963

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)

RN 648864-11-3 USPATFULL

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



=>

=> fil reg; d stat que 14

FILE "REGISTRY" ENTERED AT 15:08:23 ON 11 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7  
 DICTIONARY FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*

\*\*\*\*\*


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:



<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1


STR



Ak @12



ring or  
chain node



*Cy = any cyclic group*  
*Hy = heterocycle*

REP G1=(0-2) CH2  
VAR G3=H/X/12  
VAR G5=14/COOH/18/20/21/22/25

NODE ATTRIBUTES:

NSPEC IS RC AT 19  
CONNECT IS E2 RC AT 8  
CONNECT IS E1 RC AT 12  
CONNECT IS E1 RC AT 16  
DEFAULT MLEVEL IS ATOM  
GGCAT IS MCY AT 26  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS E2 C E3 N AT 26

*heterocycle at node 26 is monocyclic  
with 2 carbons & 3 nitrogens*

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L4 450 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 54293 ITERATIONS  
SEARCH TIME: 00.00.01

450 ANSWERS

=> fil capl uspatf toxcenter; s 14  
FILE 'CAPLUS' ENTERED AT 15:08:32 ON 11 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:08:32 ON 11 APR 2005  
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXGENTHER' ENTERED AT 15:08:32 ON 11 APR 2005  
 COPYRIGHT (C) 2005 ACS

L10 15 L4

=&gt; dup rem 110

PROCESSING COMPLETED FOR L10

L11 12 DUP REM L10 (3 DUPLICATES REMOVED)


ANSWERS '1-7' FROM FILE CAPLUS

ANSWERS '8-12' FROM FILE USPATFULL

=&gt; d libbib ed abs hitstr 1-12; fil cao; s 14

L11 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2004:60479 CAPLUS  
 DOCUMENT NUMBER: 140:128414  
 TITLE: Preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1  
 receptor modulators  
 INVENTOR(S): Barrett, Terrance D.; Breitenbacher, J. Guy; Gomez,  
 Laurent; Hack, Michael D.; Huang, Liming; McClure,  
 Kelly J.; Morton, Magda F.; Sehorn, Clark A.;  
 Shankley, Nigel P.  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.  
 SOURCE: PCT Int. Appl., 326 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007463	A1	20040122	WO 2003-US20787	20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004067983	A1	20040408	US 2003-612150	20030702
PRIORITY APPLN. INFO.:			US 2002-393493P	P 20020703
OTHER SOURCE(S):	MARPAT	140:128414		
ED Entered STN:	26 Jan 2004			
GI				




AB The title compds. [I; R1 = 1- or 2-position substituent selected from H, (un)substituted Ph, naphthyl, etc.; R2 = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R3 = H, halo, alkyl; n = 0-2; R4 = H, halo, alkyl, absent; Ar = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R5 = CO2R6 (wherein R6 = H, alkyl), CONR7R8 (R7, R8 = H, alkyl, cycloalkyl; or NR7R8 = 5-7 membered ring), tetrazolyl, etc.], useful as CCK-1 receptor modulators, were prepared. E.g., a multi-step synthesis of (S)-II which showed pKi of 8.0 against CCK-1 receptor binding, was given. Pharmaceutical composition comprising the title compound was claimed.

IT 648862-87-7P 648862-96-8P 648862-98-0P  
648863-12-1P 648863-73-4P 648864-29-3P  
648864-52-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)


RN 648862-87-7 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)- $\alpha$ -(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-96-8 CAPLUS


CN 1H-Indole-3-acetic acid,  $\alpha$ -[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-ylmethyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 648862-98-0 CAPLUS  
 CN 1H-Indole-3-acetic acid,  $\alpha$ -[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 648863-12-1 CAPLUS  
 CN 1H-Pyrazole-3-propanoic acid, 5-(4-bromophenyl)- $\alpha$ -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648863-73-4 CAPLUS  
 CN Benzeneacetic acid, 3-chloro-alpha-[[5-(3,4-dichlorophenyl)-1-(4-ethoxyphenyl)-1H-pyrazol-3-yl]methylene]-, (alphaZ)- (9CI) (CA INDEX)


NAME)

Double bond geometry as shown.




RN 648864-29-3 CAPLUS

CN 1H-1,2,4-Triazole, 3-[[3-[(4-methylphenyl)-1H-pyrazol-3-yl]-2-(3-methylphenyl)propyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 648864-52-2 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- $\alpha$ -(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

IT 119540-46-4P 119540-49-7P 648861-58-9P  
 648861-60-3P 648861-62-5P 648861-65-8P  
 648861-67-0P 648861-70-5P 648861-72-7P  
 648861-74-9P 648861-76-1P 648861-78-3P

648861-80-7P 648861-82-9P 648861-84-1P  
648861-86-3P 648861-88-5P 648861-90-9P  
648861-92-1P 648861-94-3P 648861-96-5P  
648861-98-7P 648862-00-4P 648862-02-6P  
648862-05-9P 648862-07-1P 648862-09-3P  
648862-11-7P 648862-13-9P 648862-15-1P  
648862-17-3P 648862-19-5P 648862-21-9P  
648862-23-1P 648862-25-3P 648862-27-5P  
648862-29-7P 648862-31-1P 648862-33-3P  
648862-35-5P 648862-37-7P 648862-39-9P  
648862-41-3P 648862-43-5P 648862-45-7P  
648862-47-9P 648862-49-1P 648862-51-5P  
648862-53-7P 648862-55-9P 648862-57-1P  
648862-59-3P 648862-61-7P 648862-63-9P  
648862-65-1P 648862-67-3P 648862-69-5P  
648862-71-9P 648862-73-1P 648862-75-3P  
648862-77-5P 648862-79-7P 648862-81-1P  
648862-83-3P 648862-85-5P 648862-90-2P  
648862-92-4P 648862-94-6P 648863-00-7P  
648863-02-9P 648863-06-3P 648863-08-5P  
648863-10-9P 648863-14-3P 648863-16-5P  
648863-18-7P 648863-20-1P 648863-22-3P  
648863-24-5P 648863-26-7P 648863-28-9P  
648863-31-4P 648863-33-6P 648863-35-8P  
648863-37-0P 648863-39-2P 648863-41-6P  
648863-43-8P 648863-45-0P 648863-47-2P  
648863-49-4P 648863-51-8P 648863-53-0P  
648863-55-2P 648863-57-4P 648863-59-6P  
648863-61-0P 648863-63-2P 648863-65-4P  
648863-67-6P 648863-69-8P 648863-71-2P  
648863-75-6P 648863-77-8P 648863-79-0P  
648863-81-4P 648863-83-6P 648863-85-8P  
648863-87-0P 648863-89-2P 648863-91-6P  
648863-93-8P 648863-95-0P 648863-97-2P  
648863-99-4P 648864-01-1P 648864-03-3P  
648864-05-5P 648864-07-7P 648864-09-9P  
648864-11-3P 648864-13-5P 648864-15-7P  
648864-17-9P 648864-19-1P 648864-21-5P  
648864-23-7P 648864-25-9P 648864-27-1P  
648864-31-7P 648864-33-9P 648864-35-1P  
648864-37-3P 648864-39-5P 648864-41-9P  
648864-43-1P 648864-45-3P 648864-48-6P  
648864-50-0P 648864-54-4P 648864-56-6P  
648864-58-8P 648864-60-2P 648864-62-4P  
648864-64-6P 648864-66-8P 648864-68-0P  
648864-70-4P 648864-72-6P 648864-74-8P  
648864-76-0P 648864-78-2P 648864-80-6P  
648864-82-8P 648864-84-0P 648864-86-2P  
648864-88-4P 648864-90-8P 648864-92-0P  
648864-94-2P 648864-96-4P 648864-98-6P  
648865-00-3P 648865-02-5P 648865-04-7P  
648865-06-9P 648865-08-1P 648865-10-5P  
648865-12-7P 648865-14-9P 648865-16-1P  
648865-18-3P 648865-20-7P 648865-22-9P  
648865-24-1P 648865-26-3P 648865-28-5P  
648865-30-9P 648865-32-1P 648865-34-3P  
648865-36-5P 648865-38-7P 648865-40-1P  
648865-42-3P 648865-44-5P 648865-46-7P  
648865-48-9P 648865-50-3P 648865-52-5P  
648865-54-7P 648865-56-9P 648865-58-1P


648865-60-5P 648865-62-7P 648865-64-9P  
 648865-66-1P 648865-68-3P 648865-70-7P  
 648865-72-9P 648865-74-1P 648865-76-3P  
 648865-78-5P 648865-80-9P 648865-82-1P  
 648865-84-3P 648865-86-5P 648865-88-7P  
 648865-90-1P 648865-92-3P 648865-94-5P  
 648865-96-7P 648865-98-9P 648866-00-6P  
 648866-02-8P 648866-04-0P 648866-06-2P  
 648866-08-4P 648866-10-8P 648866-12-0P  
 648866-14-2P 648866-16-4P 648866-18-6P  
 648866-20-0P 648866-22-2P 648866-24-4P  
 648866-26-6P 648866-28-8P 648866-30-2P  
 648866-32-4P 648866-34-6P 648866-36-8P  
 648866-38-0P 648866-40-4P 648866-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)


RN 119540-46-4 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ ,5-bis(4-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 119540-49-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)-5-(4-methylphenyl)-alpha-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 648861-58-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-alpha-(3-methylphenyl)-, sodium salt, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● Na

RN 648861-60-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-alpha-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648861-62-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-alpha-(3-methylphenyl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 648861-65-8 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, alpha,1-bis(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648861-67-0 CAPLUS  
 CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methoxyphenyl)-1-(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648861-70-5 CAPLUS  
 CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-1-(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648861-72-7 CAPLUS  
 CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- $\alpha$ ,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648861-74-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(4-chlorophenyl)-1-(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648861-76-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(2-chlorophenyl)-1-(4-methoxyphenyl)- $\alpha$ -1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 648861-78-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(2-chlorophenyl)- $\alpha$ -(3-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 648861-80-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)

RN 648861-82-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)- $\alpha$ -(3-methoxyphenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648861-84-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -3-benzofuranyl-1,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 648861-86-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- $\alpha$ -2-naphthalenyl-5-phenyl- (9CI) (CA INDEX NAME)


RN 648861-88-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- $\alpha$ -(3-nitrophenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-90-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -1,3-benzodioxol-4-yl-5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-92-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)- $\alpha$ -(2,3-difluorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-94-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)- $\alpha$ -(2-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 648861-96-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-alpha-(3-ethoxyphenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-98-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-alpha-[2-fluoro-3-(trifluoromethyl)phenyl]phenyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-00-4 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)-5-(4-phenoxyphenyl)-alpha-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-02-6 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- $\alpha$ -[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-05-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)- $\alpha$ -(3-iodophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-07-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)- $\alpha$ -(3,5-dimethylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648862-09-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-5-(4-methylphenyl)- $\alpha$ -[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)

RN 648862-11-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- $\alpha$ -1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 648862-13-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)-alpha-1-naphthalenyl-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648862-15-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)-alpha-1-naphthalenyl-, (alphaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648862-17-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)-, (9CI) (CA INDEX NAME)



RN 648862-19-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)-, ( $\alpha\text{R}$ )-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648862-21-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)-, ( $\alpha\text{S}$ )-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648862-23-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -[1,1'-biphenyl]-4-yl-5-(4-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-25-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)- $\alpha$ -(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-27-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)- $\alpha$ -(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-29-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)- $\alpha$ -(3-methoxyphenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-31-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-chlorophenyl)-5-(4-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-33-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-chlorophenyl)-5-(4-methylphenyl)- $\alpha$ -1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 648862-35-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ ,1-bis(3-chlorophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-37-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methylphenyl)-1,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-39-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)- $\alpha$ -phenyl-1-[4-

(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 648862-41-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-alpha-(3-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-43-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, alpha-(2-chlorophenyl)-5-(4-methylphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 648862-45-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)-1-(phenylmethyl)-alpha-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-47-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)- $\alpha$ -2-naphthalenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 648862-49-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(2,3-dichlorophenyl)-1-(3,4-dichlorophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-51-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methylphenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 648862-53-7 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 3-(3,4-dichlorophenyl)-1-methyl-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-55-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-methyl-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-57-1 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-cyclohexyl-α-(3-methylphenyl)-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 648862-59-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-cyclohexyl-alpha-(3-methylphenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 648862-61-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, alpha-(3-methylphenyl)-5-(2-naphthalenyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 648862-63-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-[4-(1,1-dimethylethyl)phenyl]- $\alpha$ -(3-methylphenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-65-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)- $\alpha$ -(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-67-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(2-chlorophenyl)- $\alpha$ -(3-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648862-69-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(2,4-dichlorophenyl)- $\alpha$ -(3-methylphenyl)-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)

RN 648862-71-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3-chlorophenyl)-1-(2,4-dichlorophenyl)- $\alpha$ -(3-methylphenyl)- (9CI) (CA INDEX NAME)


RN 648862-73-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid,  $\alpha$ -(3-methylphenyl)-5-[4-(phenylmethoxy)phenyl]-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-75-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-[4-(dimethylamino)phenyl]- $\alpha$ -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-77-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3-methoxy-4-methylphenyl)- $\alpha$ -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-79-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-[3-(cyclopentyloxy)-4-methoxyphenyl]- $\alpha$ -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-81-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-bromo-3-methylphenyl)-alpha-(3-methylphenyl)-1-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648862-83-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(7-methoxy-2-benzofuranyl)-alpha-(3-methylphenyl)-1-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648862-85-5 CAPLUS


CN 1H-Pyrazole-3-propanamide, N-[ (1R,2R)-2-hydroxycyclohexyl]-1-(4-methoxyphenyl)-α-(3-methylphenyl)-5-(4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 648862-90-2 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)-N,N-dimethyl-α-(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-92-4 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)-N-methyl-α-(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-94-6 CAPLUS

CN Piperazine, 1-[3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]-2-(3-methylphenyl)-1-oxopropyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 648863-00-7 CAPLUS

CN 1H-Indole-3-acetic acid, α-[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]- (9CI) (CA INDEX NAME)